Free Trial
NASDAQ:GRCL

Gracell Biotechnologies (GRCL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$10.25
$10.25
50-Day Range
$10.14
$10.35
52-Week Range
$1.40
$10.44
Volume
N/A
Average Volume
1.32 million shs
Market Capitalization
$744.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.88

Gracell Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
15.9% Upside
$11.88 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.92) to ($0.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.17 out of 5 stars

Medical Sector

902nd out of 915 stocks

Biotechnology Industry

9th out of 10 stocks

GRCL stock logo

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

GRCL Stock News Headlines

GRCL Mar 2024 10.000 call(CONTR
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Inc. (GRCL)
GRCL Mar 2024 2.500 call
GRCL Gracell Biotechnologies Inc.
See More Headlines
Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2021
Today
6/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:GRCL
Fax
N/A
Employees
314
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.88
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+15.9%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$-88,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60,000.00
Price / Sales
12,415.83
Book Value
$2.95 per share

Miscellaneous

Free Float
52,328,000
Market Cap
$744.95 million
Optionable
Optionable
Beta
-0.33
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Wei Cao BM (Age 65)
    Ph.D., Founder, Chairman & CEO
  • Dr. Yili Xie M.B.A. (Age 53)
    Ph.D., Chief Financial Officer
  • Dr. Samuel Suhua Zhang M.B.A. (Age 56)
    Ph.D., Chief Business Officer
  • Dr. Wendy Li M.D. (Age 65)
    Chief Medical Officer
  • Ms. Erin Li
    Executive Officer

GRCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GRCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRCL, but not buy additional shares or sell existing shares.
View GRCL analyst ratings
or view top-rated stocks.

What is Gracell Biotechnologies' stock price target for 2024?

8 equities research analysts have issued twelve-month price objectives for Gracell Biotechnologies' stock. Their GRCL share price targets range from $10.00 to $20.00. On average, they anticipate the company's stock price to reach $11.88 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price.
View analysts price targets for GRCL
or view top-rated stocks among Wall Street analysts.

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.18. The business had revenue of $0.06 million for the quarter.

When did Gracell Biotechnologies IPO?

Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Equitec Proprietary Markets LLC (0.00%).

This page (NASDAQ:GRCL) was last updated on 6/15/2024 by MarketBeat.com Staff

From Our Partners